New Medicines Committee Briefing July 2011

Size: px
Start display at page:

Download "New Medicines Committee Briefing July 2011"

Transcription

1 New Medicines Committee Briefing July 2011 Pramipexole immediate-release (Mirapexin ) and Pramipexole modifiedrelease (Mirapexin prolonged release) for the treatment of Parkinson s Disease Pramipexole is to be reviewed for use within: Primary Care Secondary Care Summary: Pramipexole is a non-ergot dopamine agonist used in the treatment of Parkinson s disease (PD) 1,2 Pramipexole is available as an immediate-release (IR) formulation administered three times daily and a modified-release (MR) preparation administered once daily 1,2 Pramipexole IR and pramipexole MR are licensed for treatment of the signs and symptoms of idiopathic Parkinson's disease alone (i.e. without levodopa) or in combination with levodopa ie over the course of the disease, through to the late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or on off fluctuations) 1,2 NICE recommends dopamine agonists as a class as a first-choice option for initial therapy for early PD and as an adjuvant to levodopa in later PD 3 SMC has accepted pramipexole MR tablets for use within NHS Scotland 4 reviewed IR formulation) (SMC have not SIGN recommends that oral/transdermal dopamine agonists may be considered for the treatment of early PD with motor symptoms and for the management of motor complications in patients with advanced PD 5 Pramipexole IR has been shown to be an effective treatment for the symptoms of PD both as monotherapy in patients with early disease 6,7 and in combination with levodopa in patients with advanced PD 8 Pramipexole MR has been shown to be effective and well tolerated for the treatment of PD, either alone 9,10,11 or in combination with levodopa 12 1

2 Formulary application: Consultant submitting application: Clinical Director supporting application: Dr Jonathan Partridge (Consultant Neurologist) Dr Simon Ellis Following a review of BNF section of the formulary it was suggested by Dr Carl Mann (Consultant Neurologist) that pramipexole should be added to the formulary; Dr Jonathan Partridge agreed to support the application at the New Medicine Committee. Current treatment choice in Parkinson s disease is largely dependent on symptoms with the line of treatment being more general than specific ie a monoamine oxidase B (MAO-B) inhibitor, then a dopamine agonist, then levodopa, then a catechol-o-methyltransferase (COMT) inhibitor; pramipexole is currently being prescribed second-line in addition to a mononamine oxidase B inhibitor in patients where tremor or low-mood is a problem. Background: Parkinson s disease is a neurodegenerative disorder characterised by loss of dopaminergic neurons in the substantia nigra. Classic presenting symptoms include hypokinesia, bradykinesia, rigidity and tremor at rest. Parkinson s disease affects about 120,000 people in the UK (about 200 per 100,000) with symptoms appearing usually in patients aged over 50 years 13. Drug therapy does not prevent disease progression, but it improves most patients quality of life. The symptoms of PD are not usually treated until they cause significant interruption of daily activities 14. Levodopa (in combination with a dopa-decarboxylase inhibitor) is the most potent antiparkisonian drug and is the mainstay of treatment for the majority of the course of the disease in all patients. A complication of long-term levodopa treatment is motor complications including dyskinesias and response fluctuations, or on/off episodes. Dopamine-receptor agonists have a direct action on dopamine receptors and are used in early PD and also used as an adjunct to levodopa in more advanced disease. Non-ergot-derived dopamine-receptor agonists include pramipexole, ropinirole and rotigotine and ergot-derived dopamine-receptor agonists are bromocriptine, cabergoline and pergolide; ergot-derived dopamine-receptor agonists are associated with fibrotic reactions. Monoamine oxidase B inhibitors (rasagiline and selegiline) are used as monotherapy and as adjuncts to levodopa for the alleviation of end-of-dose fluctuations in patients with later disease. Catechol-O-methyltransferase inhibitors (entacapone and tolcapone) prevent the peripheral breakdown of levodopa and are used with co-beneldopa and co-careldopa for patients with PD who experience end-of-dose deterioration and cannot be stabilised on these combinations 14. 2

3 Current formulary status: The North Staffordshire Joint Formulary currently lists the following agents: 4.9 DRUGS USED IN PARKINSONISM AND RELATED DISORDERS Parkinson's disease: diagnosis and management in primary and secondary care NICE Clinical Guideline CG35 (date 06/06) Dopaminergic drugs used in Parkinson s disease CSM Amantadine 2 Restriction: Initiation by specialist Co-beneldopa (Madopar preparations) 2 Restriction: Initiation by specialist Co-careldopa (Sinemet preparations) 2 Restriction: Initiation by specialist Entacapone 2 Restriction: Initiation by specialist MTRAC Restriction: Initiation and stabilisation by Ropinirole 2 specialist MTRAC Rotigotine 2 Restriction: Patients that are NBM or have swallowing difficulties. Prescribing should be MTRAC reviewed on discharge from secondary care Selegiline 2 Restriction: Initiation by specialist Entacapone MTRAC recommendation VS99/01 (date 01/99) A COMT inhibitor for the treatment of Parkinson s Disease RESTRICTED USE Ropinirole MTRAC recommendation VS00/01 (date 01/00) A dopamine agonist for the treatment of Parkinson s Disease RESTRICTED USE Ropinirole MTRAC recommendation VS07/01 (date 01/07) For the treatment of restless leg syndrome Q3, Category A suitable for prescribing in primary care Therapeutic class and mode of action: Pramipexole is non-ergot dopamine agonist that alleviates motor deficit in PD by stimulating dopamine receptors in the striatum 1,2. Licensed indication: Treatment of the signs and symptoms of idiopathic Parkinson's disease alone (i.e. without levodopa) or in combination with levodopa ie over the course of the disease, through to the late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end-of-dose or on off fluctuations). 1,2 Mirapexin is also licensed for the symptomatic treatment of moderate to severe Restless Legs Syndrome 1 - this indication is not included in the review. 3

4 Dosage and administration: Immediate-release tablets: Dose * : Initially 88 micrograms 3 times daily, dose doubled every 5 7 days if tolerated to 350 micrograms 3 times daily; further increased if necessary by 180 micrograms 3 times daily at weekly intervals; max. 3.3 mg daily in 3 divided doses 1 Administration: With or without food; swallowed with water 1 Renal impairment: Renal impairment requires dose reduction (slower dose titration and adjustment) 14 Hepatic impairment: No change in dosage required 1 * Doses and strengths are stated in terms of pramipexole (base); equivalent strengths in terms of pramipexole dihydrochloride monohydrate (salt) are as follows: 88 micrograms base 125 micrograms salt; 180 micrograms base 250 micrograms salt; 350 micrograms base 500 micrograms salt; 700 micrograms base 1 mg salt Modified-release tablets: Dose $ : Initially 260 micrograms once daily, dose doubled every 5 7 days to 1.05 mg once daily; further increased if necessary by 520 micrograms daily at weekly intervals; max mg once daily (maintenance dose usually mg daily) 2 SMC recommends that patient taking pramipexole immediate-release tablets can be switched to modified-release tablets overnight at the same total daily dose 4 Administration: With or without food; swallowed whole with water 2 Renal impairment: Renal impairment requires dose reduction (slower dose titration and adjustment); avoid in patients with an egfr of less than 30ml/min 14 Hepatic impairment: No change in dosage required 2 $ Doses and strengths are stated in terms of pramipexole (base); equivalent strengths in terms of pramipexole dihydrochloride monohydrate (salt) are as follows: 260 micrograms base 375 micrograms salt; 520 micrograms base 750 micrograms salt; 1.05 mg base 1.5 mg salt; 4

5 1.57 mg base 2.25 mg salt; 2.1 mg base 3 mg salt; 2.62 mg base 3.75 mg salt; 3.15 mg base 4.5 mg salt Presentation: Immediate-release tablets: 30 tablet pack only of following strength: 88 micrograms 30 and 100-tablet packs of the following strengths: 180 micrograms, 350 micrograms, 700 micrograms Modified-release tablets: 30 tablet packs of the following strengths: 260 micrograms, 520 micrograms, 1.05 mg, 1.57 mg, 2.1 mg, 2.62 mg, 3.15 mg Guidance: NICE Guidance 3 : NICE guidance published Relevant guidance Yes NICE Clinical Guideline Parkinson's disease: diagnosis and management in primary and secondary care (June 2006) NICE guidance stated that it was not possible to identify a universal first-choice drug therapy for either early PD or as an adjuvant drug therapy for later PD; the guidance recommended the following first-choice treatment options: Initial therapy for early PD- levodopa, dopamine agonists and MAO-B inhibitors Adjunctive therapy for later PD to reduce motor complications and improve quality of life in patients taking levodopa- dopamine agonists, MAO-B inhibitors and COMT inhibitors For dopamine agonists NICE recommends: If side effects prevent titration to agonists clinically efficacious dose, replace with another dopamine agonist or another drug class. In view of the monitoring required with ergot-derived dopamine-agonists, a non-ergot-derived agonists should be preferred in most cases. The guidance recommended that when choosing treatment clinical and lifestyle preferences and patient preference, after informing the patient of the short- and long-term benefits and drawbacks of drug classes, should be taken into account. Scottish Medicines Consortium (SMC) 4 : SMC recommended use within NHS Scotland: Yes Following an abbreviated submission the SMC accepted modified-release tablets for the licensed indication; SMC noted that in patients for whom pramipexole is appropriate, the prolonged- 5

6 release formulation can provide the same daily dose as existing immediate-release formulations, with the benefit of once-daily rather than thrice daily dosing, at an equivalent cost Cochrane Review 15,16 : Dopamine agonist therapy in early Parkinson s disease 15 : Authors concluded that the meta-analysis confirmed that motor complications are reduced with dopamine agonists compared to levodopa, but also established that other important side-effects are increased and symptom control is poorer with agonists; larger, long-term comparative trials assessing patient-rated quality of life are needed to assess more reliably the balance of benefits and risks of dopamine agonists compared to levodopa. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications 16 : Authors concluded that compared to placebo, adjuvant therapy reduces off-time, levodopa dose, and improves UPDRS scores in PD patients who develop motor complications on levodopa therapy. However, this is at the expense of increased dyskinesia and numerous other sideeffects. Indirect comparisons suggest that dopamine agonist therapy may be more effective than COMTI and MAOBI therapy, which have comparable efficacy. However, as indirect comparisons should be interpreted with caution, direct head-to-head randomised trials assessing the impact of these different drug classes on overall patient-rated quality of life are needed. Scottish Intercollegiate Guidelines Network (SIGN) 5 : SIGN guidelines published Relevant guidelines Yes 113- Diagnosis and pharmacological management of Parkinson s disease (January 2010) SIGN recommends that oral/transdermal dopamine agonists may be considered for: Patients with early Parkinson s disease and motor symptoms; ergot derived dopamine agonists should not be used as first line treatment for Parkinson s disease. Management of motor complications in patients with advanced Parkinson s disease; the non-ergot agonists (ropinirole, pramipexole, and rotigotine) are preferable to the ergot agonists. MTRAC 14 MTRAC reviewed Yes (immediate-release only) MTRAC have recommended that initiation and stabilisation of pramipexole, as monotherapy or as an adjunct to levodpa, should be the responsibility of the specialist. It is then appropriate for GPs to prescribe pramipexole over the long term within the guidance of an ESCA. 6

7 Efficacy: Outcome measures used to evaluate efficacy of treatment of PD: Unified Parkinson s Disease Rating Scale (UPDRS) is a standardised scale comprising 4 sections that are evaluated by interview and clinical assessment- the higher the UPDRS score, the more severe the disease and a positive change signifies a worsening of the disease. Changes in time spent on and off can be used to evaluate drug efficacy in patients that have developed motor symptoms off time refers to periods when treatment is not working and patient activity is impaired on time refers to periods when treatment in working Immediate-release preparation Summary: pramipexole IR has been shown to be an effective treatment for the symptoms of PD both as monotherapy in patients with early disease 6,7 and in combination with levodopa in patients with advanced PD 8 Early Parkinson s Disease (as monotherapy) Shannon et al 6 a 24-week, multicentre, randomised, double-blind trial (n=335). Patients randomised to receive pramipexole (titrated to 4.5mg od; mean daily dose 3.8mg) or placebo. Pramipexole significantly decreased the UPDRS score (part II and III) from baseline compared to placebo (p<0.0001) CALM-PD 7-4-year, multi-centre, randomised, controlled trial (n=301). Patients randomised to receive 0.5mg pramipexole tds (with levodopa placebo) or 25/100mg carbidopa/levodopa 3 times daily (with pramipexole placeo). Patients allowed to titrate up for 10 weeks and could then be prescribed open-label levodopa or anti-parkinsonian medication. Initial treatment with pramipexole resulted in a significant reduction in the risk of developing dyskinesias compared with initial treatment with levodopa (24.5% v 54% risk (p<0.001)) and fewer patients experienced wearing off with initial treatment with pramipexole (47% v 63% (p=0.02)). By 48 months the occurance of dyskinesias did not significantly differ between the 2 groups. The mean improvement in the total UPDRS score from baseline to 48 months was greater in the levodopa group than in the pramipexole group. Advanced Parkinson s Disease (with levodopa) Liebermann et al 8 a 32-week, double-blind, placebo-controlled, parallel-group study (n=360). Patients randomised to receive pramipexole or placebo. Pramipexole improved motor function of patients during on and off periods, as assessed by the UPDRS score. 7

8 Modified-release preparation Summary: Pramipexole MR has been shown to be effective and well tolerated for the treatment of PD, either alone 9,10,11 or in combination with levodopa 12 ; non-inferiority to the IR formulation has been shown when used alone 9,10,11 and no clinically relevant differences in efficacy compared to the IR formulation have been shown or in combination with levodopa 12 Early Parkinson s Disease (as monotherapy) The efficacy of pramipexole MR in early PD has been assessed in 2 randomised controlled trials: A 33-week, multi-national, randomised, double-blind, placebo-controlled study- patients were randomised to receive pramipexole MR, pramipexole IR or placebo 9,10,11. Analysis was performed at week 18 9 and week At week 18, patients treated with pramipexole IR and MR showed significantly greater improvements in UPDRS II and III score than those treated with placebo (p<0.029) and at week 33 patients treated with pramipexole MR and IR showed improvements compared to placebo. Non-inferiority was demonstrated for pramipexole MR compared with IR as assessed by the UPDRS II and III score at week 33. A 33-week, randomised-controlled trial- patients randomised to receive pramipexole MR, pramipexole IR or placebo (n=259) 11. Analysis was performed at week 18 and week 33. At week 18 superiority of pramipexole MR over placebo was demonstrated; at week 33 non-inferiority was demonstrated between the 2 pramipexole formulations when comparing mean change in UPDRS II and III scores. Advanced Parkinson s Disease (with levodopa) A 33-week, randomised, controlled trial (n=517) 12 -patients randomised to receive pramipexole MR, pramipexole IR or placebo. At week 18 both pramipexole formulations were statistically superior to placebo in terms of change from baseline in UPDRS II and III score and change on off time from baseline. Although the sydy was not powered or designed to test the noninferiority of pramipexole PR compared to IR no clinically relevant differences in efficacy of the pramipexole formulations was reported. Comparison of modified-release and immediate-release tablets The manufacturer suggests that the MR preparation offers the following advantages compared to the IR formulation 17 : Improvements in patient compliance- a study concluded that in PD patients once-daily dosing is associated with significantly higher adherence than more frequent dosing; patients who were more adherent showed significantly better symptom scores 18 Less frequent fluctuations in the pramipexole plasma concentration over 24 hours leading to improved symptom control and fewer off periods 8

9 Safety and adverse effects: Contraindications: Hypersensitivity to active ingredient/excipient 1,2 Adverse effects: Driving: Commonly reported adverse effects (more frequently occurring than placebo)- nausea, dyskinesia, hypotension, dizziness, somnolence, insomnia, constipation, hallucination, headache, fatigue 1,2 Manufacturer states that adverse event rates are similar for modifiedrelease and immediate-release formulations 17 Manufacturer states: Pramipexole has been associated with somnolence and episodes of sudden sleep onset, particularly in patients with Parkinson's disease. Sudden onset of sleep during daily activities, in some cases without awareness or warning signs, has been reported uncommonly. Patients must be informed of this and advised to exercise caution while driving or operating machines during treatment with MIRAPEXIN. Patients who have experienced somnolence and/or an episode of sudden sleep onset must refrain from driving or operating machines 1,2. For additional information in adverse effects refer to the Summary of Product Characteristics 1,2. Drug Interactions: Manufacturer advises the following 1,2,14 Avoid co-administration with anti-psychotics (antagonism of effect) Reduce the dose of levodopa when pramipexole is given in combination with levodopa; doses of other anti-parkinson s medicines to be kept constant during pramipexole dose titration Consider reducing the pramipexole dose when administering with inhibitors/competitors of the active renal elimination pathway eg cimetidine, amantadine (ie increased plasma concentration) For additional drug interactions refer to the Summary of Product Characteristics 1,2. 9

10 Cost analysis Costs of in primary and secondary care: Pramipexole Pack Primary Care (exc. VAT) Secondary Care (inc. VAT) (as base) size (Drug Tariff 19 price) IR 88 micrograms (c) IR 180 micrograms (c) IR 180 micrograms *use contracted 30 pack* IR 350 micrograms (c) IR 350 micrograms *use contracted 30 pack* IR 700 micrograms (c) IR 700 micrograms *use contracted 30 pack* MR 260 micrograms MR 520 micrograms MR 1.05 mg MR 1.57 mg MR 2.1 mg MR 2.62 mg MR 3.15 mg IR= immediate-release; MR=modified-release (c)= available on contract in secondary care The cost of the modified-release formulation compared to equivalent doses of immediaterelease formulation (based on drug tariff prices) Daily dose (base) Pramipexole IR Pramipexole MR Dose Price Cost per Dose Price (30 tablets) day (30 tablets) 0.264mg 3 x 88mcg x 260mcg mg 3 x 180mcg x 520mcg mg 3 x 350mcg x 1.05 mg Cost per day 1.59mg 3 x 350mcg x 1.57 mg x 180mcg mg 3 x 700 mcg x 2.1 mg mg 3 x 700 mcg x 2.62 mg x 180mcg mg 3 x 700 mcg 3 x 350mcg x 3.15 mg

11 Expenditure in primary and secondary care for a 6-month period: (October March 2011): Pramipexole UHNS Stoke-on-Trent PCT North Staffordshire PCT (as base) IR 88 micrograms IR 180 micrograms IR 350 micrograms IR 700 micrograms MR 260 micrograms MR 520 micrograms MR 1.05 mg MR 1.57 mg MR 2.1 mg MR 2.62 mg 1020 MR 3.15 mg Estimated cost: Pramipexole is currently already in use- please refer above to expenditure data 11

12 Comparison with other therapy: Early PD as monotherapy: Usual daily dose* Cost for 28 days Class Drug Formulary status # treatment $ Dopamine agonists Rotigotine F 2-8mg daily (non-ergot derived) Ropinirole F 9-16mg Pramipexole IR A 0.264mg-3.15mg (as base) Pramipexole A 0.26mg-3.15mg MR (as base) Dopamine agonists Pergolide F mg (ergot derived) Levodopa Co-beneldopa F mg (levodopa) Co-careldopa F mg (levodopa) MAO-B inhibitor Selegeline F 10mg daily 6.87 Rasagiline A 1mg Advanced PD (in combination with L-dopa): Usual daily dose* Cost for 28 days Class Drug Formulary status # treatment $ Dopamine agonists Rotigotine F 4-16mg (non-ergot-derived) Ropinirole F 9-24mg Pramipexole IR A 0.264mg-3.15mg (as base) Pramipexole A 0.26mg-3.15mg MR (as base) Dopamine agonists Pergolide F Max. 3mg (ergot-derived) MAO-B inhibitor Selegeline F 10mg 6.87 Rasagiline A 1mg COMT inhibitor Entacapone F mg # F= formulary; NF=non-formulary; A= formulary application under consideration *Doses are for general comparison and do not imply therapeutic equivalence $ Prices from BNF

13 References 1. Mirapexin 0.088mg Tablets Summary of Product Characteristics. Boehringer Ingelheim Limited. Last updated 21/1/2011. Accessed 2/6/ Mirapexin 0.26mg prolonged-release tablets Summary of Product Characteristics. Boehringer Ingelheim Limited. Last updated 21/1/2011. Accessed 2/6/ NICE. Clinical Guideline Parkinson's disease: diagnosis and management in primary and secondary care (June 2006). Accessed via 4. Scottish Medicines Consortium (SMC). Pramipexole dihydrochloride monohydrate prolonged release tablets 0.375mg, 0.75mg, 1.5mg, 3.0mg, 4.5mg (equivalent to 0.26mg, 0.52mg, 1.05mg, 2.1mg, 3.15mg pramipexole) (Mirapexin) (No. 580/09). _2009_for_website.pdf 5. SIGN. SIGN 113: Diagnosis and pharmacological management of Parkinson s Disease (January 2010). Accessed via 6. Shannon et al. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson s disease. Neurology 1997; 49(3): The Parkinson Study Group. Pramipexole vs Levodopa as Initial Therapy for Parkinson Disease. Arch Neurol 2004; 61: Lieberman A et al. Evaluation of pramipexole in advanced Parkinson s Disease; results of a double-blind, placebo-controlled, parallel-group study. Neurology1997; 49(1): Hauser R et al. Randomised, double-blind, multicentre evaluation of pramipexole extended release once daily in early Parkinson s disease. Movement disorders 2010 e-publication DOI: /mds Cited in Boehringer Ingelheim. Mirapexin Prolonged Release Formulary Request Information. 10. Salin et al. Double-blind evaluation of mainternance of pramipexole extended-release in Early Parkinson s Disease. AAN, Seattle, May 2009; P Poewe et al. Pramipexole extended-release os effective in early Parkinson s Disease. The Movement Disporder Society 13 th Annual International Congress of Parkinson s Disease and Movement Disoorders June 2009; Paris, France. Abstract WE Schapira et al. Efficacy and safety of pramipexole extended release for advanced Parkinson s disease. The Movement Disporder Society 13 th Annual International Congress of Parkinson s Disease and Movement Disoorders June 2009; Paris, France. Poster P Midlands Therapeutics Review & Advisory Committee. Verdict and Summary Pramipexole (Mirapexin ) for the treatment of Parkinson s Disease (June 2002). Accessed via British National Formulary No 61 (March 2011). BMJ and Pharmaceutical Press: London. 15. Stowe R et al. Dopamine agonist therapy in early Parkinson s disease. Cochrane Database of Systematic Reviews 2008, Issue (2): CD Stowe R et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson s disease patients with motor complications. Cochrane Database of Systematic Reviews 2010, Issue (7): CD

14 17. Boehringer Ingelheim. Mirapexin Prolonged Release Formulary Request Information. 18. Grosset et al. Adherence to antiparkinson medication in a multicenter European study. Movement Disorders 2009; 24(6): Department of Health and Welsh Assembly Government (April 2011). National Health Service England and Wales Drug Tariff. TSO: London Produced by Julie Shenton Primary / Secondary Care Interface Pharmacist University Hospital of North Staffordshire Telephone: julie.shenton@uhns.nhs.uk Produced for use within the NHS. Not to be reproduced for commercial purposes 14

15 15

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium rotigotine 2mg/24 hours, 4mg/24 hours, 6mg/24 hours, 8mg/24 hours transdermal patch (Neupro ) (No: 289/06) Schwarz Pharma Ltd. 7 July 2006 The Scottish Medicines Consortium

More information

Re-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.

Re-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd. Scottish Medicines Consortium Re-Submission rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd 10 November 2006 The Scottish Medicines Consortium (SMC) has completed

More information

Final Appraisal Report. ) for the treatment of idiopathic Parkinson s disease. Ropinirole prolonged-release (Requip XL. GlaxoSmithKline UK

Final Appraisal Report. ) for the treatment of idiopathic Parkinson s disease. Ropinirole prolonged-release (Requip XL. GlaxoSmithKline UK Final Appraisal Report Ropinirole prolonged-release (Requip XL ) for the treatment of idiopathic Parkinson s disease GlaxoSmithKline UK Advice No: 1409 August 2009 Recommendation of AWMSG Ropinirole prolonged-release

More information

TRANSPARENCY COMMITTEE OPINION. 18 March 2009

TRANSPARENCY COMMITTEE OPINION. 18 March 2009 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 18 March 2009 REQUIP LP 2 mg extended-release tablet Box of 21 tablets (CIP: 379 214-8) Box of 28 tablets (CIP: 379

More information

PARKINSON S MEDICATION

PARKINSON S MEDICATION PARKINSON S MEDICATION History 1940 50 s Neurosurgeons operated on basal ganglia. Improved symptoms. 12% mortality 1960 s: Researchers identified low levels of dopamine caused Parkinson s leading to development

More information

Anticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product

Anticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review:

More information

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to crystallization of the drug, which caused unreliable drug

More information

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August

CENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 3Q17 July August BRAND NAME Xadago GENERIC NAME Safinamide MANUFACTURER Newron Pharmaceuticals SpA holds license; granted approval. US WorldMeds, LLC exclusive licensee and distributor in the U.S. DATE OF APPROVAL March

More information

SIFROL â. Contraindications Hypersensitivity to pramipexole or any other component of the product.

SIFROL â. Contraindications Hypersensitivity to pramipexole or any other component of the product. SIFROL â Composition 1 tablet contains 0.088, 0.18 & 0.7 mg (S) 2 amino 4,5,6,7-tetrahydro-6-propylamino-benzothiazole (= pramipexole base) equivalent to 0.125, 0.25 & 1 mg of pramipexole dihydrochloride

More information

New Medicines Committee Briefing November 2011 Abstral (sublingual fentanyl citrate tablet) for the management of breakthrough cancer pain

New Medicines Committee Briefing November 2011 Abstral (sublingual fentanyl citrate tablet) for the management of breakthrough cancer pain New Medicines Committee Briefing November 2011 Abstral (sublingual fentanyl citrate tablet) for the management of breakthrough cancer pain Abstral is to be reviewed for use within: Primary Care Secondary

More information

Medications used to treat Parkinson s disease

Medications used to treat Parkinson s disease Medications used to treat Parkinson s disease Edwin B. George, M.D., Ph.D. Director of Wayne State University Movement Disorder Clinic University Health Center Neurology Clinic University Health The John

More information

Parkinson s Disease Prescribing Guidelines for use in Primary and Secondary Care

Parkinson s Disease Prescribing Guidelines for use in Primary and Secondary Care Parkinson's Disease Prescribing Guidelines for use in Primary and Secondary Care 2017 Parkinson s Disease Prescribing Guidelines for use in Primary and Secondary Care Document Description Document Type

More information

Suffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and futher notice)

Suffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and futher notice) Suffolk PCT Drug & Therapeutics Committee New Medicine Report (Adopted by the CCG until review and futher notice) This drug has been reviewed because it is a product that may be prescribed in primary care.

More information

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Drug Therapy of Parkinsonism Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Parkinsonism is a progressive neurological disorder of muscle movement, usually

More information

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York Program Highlights David Swope, MD Associate Professor of Neurology Mount Sinai Health System New York, New York Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone

More information

Opicapone is a peripheral, selective and reversible catechol-o-methyltransferase (COMT) inhibitor 1.

Opicapone is a peripheral, selective and reversible catechol-o-methyltransferase (COMT) inhibitor 1. New Medicines Committee Briefing June 2017 Opicapone (Ongentys ) as adjunctive therapy in adult patients with Parkinson s disease and end-of-dose motor fluctuations Opicapone (Ongentys ) is to be reviewed

More information

Dorset Medicines Advisory Group SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE

Dorset Medicines Advisory Group SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE SHARED CARE GUIDELINES FOR PRESCRIBING ENTACAPONE (INCLUDING IN COMBINATION) OR OPICAPONE IN PARKINSON S DISEASE INDICATION By inhibiting metabolism of levodopa, entacapone or opicapone allow a reduction

More information

Guidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth

Guidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth Index No: MMG48 Guidelines for acute treatment of patients with Parkinson s disease including those who are nil by mouth Version: 2.0 Date ratified: November 2017 Ratified by: (Name of Committee) Name

More information

Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University

Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University I have no financial interest with any entity producing marketing, re-selling,

More information

Prior Authorization with Quantity Limit Program Summary

Prior Authorization with Quantity Limit Program Summary Gocovri (amantadine) Prior Authorization with Quantity Limit Program Summary This prior authorization applies to Commercial, NetResults A series, SourceRx and Health Insurance Marketplace formularies.

More information

Clinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: Last Review Date: Line of Business: Commercial

Clinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: Last Review Date: Line of Business: Commercial Clinical Policy: Safinamide (Xadago) Reference Number: CP.CPA.308 Effective Date: 05.16.17 Last Review Date: 08.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy

More information

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Assistant Professor of Neurology + Overview n Brief review of Parkinson s disease (PD) n Clinical manifestations n Pathophysiology

More information

Continuous dopaminergic stimulation

Continuous dopaminergic stimulation Continuous dopaminergic stimulation Angelo Antonini Milan, Italy GPSRC CNS 172 173 0709 RTG 1 As PD progresses patient mobility becomes increasingly dependent on bioavailability of peripheral levodopa

More information

XADAGO (safinamide) oral tablet

XADAGO (safinamide) oral tablet XADAGO (safinamide) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy Coverage

More information

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Pharmacologic Treatment of Parkinson s Disease Nicholas J. Silvestri, M.D. Associate Professor of Neurology + Disclosures n NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS TO REPORT + Learning

More information

Rotigotine patches (Neupro) in early Parkinson s disease Edited by AdRes Health Economics & Outcomes Research

Rotigotine patches (Neupro) in early Parkinson s disease Edited by AdRes Health Economics & Outcomes Research Rotigotine patches (Neupro) in early Parkinson s disease Edited by AdRes Health Economics & Outcomes Research Synthetic DRUG PROFILE Introduction Parkinson s disease (PD) is a neurodegenerative disorder

More information

SIFROL Composition Properties Indication

SIFROL Composition Properties Indication SIFROL Boehringer Composition 1 tablet contains: 0.125, 0.25 or 1.0 mg, (S)-2- amino-4,5,6,7-tetrahydro-6-propylamino-benzothiazole dihydrochloride monohydrate equivalent to 0.088, 0.18 or 0.7 mg pramipexole

More information

Clinical Guideline for the management of inpatients with Parkinson s disease

Clinical Guideline for the management of inpatients with Parkinson s disease Clinical Guideline for the management of inpatients with Parkinson s disease Introduction: Parkinson s disease (PD) is the second most common neurodegenerative disorder, characterised by bradykinesia,

More information

ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM

ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM ACUTE MANAGEMENT OF PARKINSON S PATIENTS WHO ARE NIL BY MOUTH (NBM) OR WHO HAVE A COMPROMISED SWALLOW NHS LANARKSHIRE PARKINSON S TEAM 1 CONTENTS: TOPIC PAGE Introduction 3 What should you do when a PD

More information

10th Medicine Review Course st July Prakash Kumar

10th Medicine Review Course st July Prakash Kumar 10th Medicine Review Course 2018 21 st July 2018 Drug Therapy for Parkinson's disease Prakash Kumar National Neuroscience Institute Singapore General Hospital Sengkang General Hospital Singhealth Duke-NUS

More information

PDL Class: Parkinson s Drugs

PDL Class: Parkinson s Drugs Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-945-5220 Fax 503-947-1119 Class Update: Parkinson s Drugs Month/Year of Review: September 2013 Date of Last Review:

More information

What is the best medical therapy for early Parkinson's disease? Medications Commonly Used for Parkinson's Disease

What is the best medical therapy for early Parkinson's disease? Medications Commonly Used for Parkinson's Disease FPIN's Clinical Inquiries Treatment of Early Parkinson's Disease Clinical Question What is the best medical therapy for early Parkinson's disease? Evidence-Based Answer Treatment of early Parkinson's disease

More information

New Medicines Committee Briefing November 2011

New Medicines Committee Briefing November 2011 New Medicines Committee Briefing November 2011 Paliperidone long-acting injection (Xeplion ) for schizophrenia Paliperidone palmitate long-acting injection (Xeplion ) is to be reviewed for use within:

More information

Parkinson s Disease Medications: Professionals Edition

Parkinson s Disease Medications: Professionals Edition Parkinson s Disease Clinic and Research Center University of California, San Francisco 505 Parnassus Ave., Rm. 795-M, Box 0114 San Francisco, CA 94143-0114 (415) 476-9276 http://pdcenter.neurology.ucsf.edu

More information

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease 5/11/16 PARKINSON S DISEASE Parkinson s disease Prevalence increases with age (starts 40s60s) Seen in all ethnic groups, M:F about 1.5:1 Second most common neurodegenerative disease Genetics role greater

More information

KEY SUMMARY. Mirapexin /Sifrol (pramipexole): What it is and how it works. What is Mirapexin /Sifrol (pramipexole)?

KEY SUMMARY. Mirapexin /Sifrol (pramipexole): What it is and how it works. What is Mirapexin /Sifrol (pramipexole)? KEY SUMMARY 1. Mirapexin /Sifrol (pramipexole*) is a selective non-ergot dopamine agonist approved as immediate release since 1997 for the treatment of the signs and symptoms of idiopathic Parkinson's

More information

New Medicine Recommendation Opicapone (Ongentys ) 50mg hard capsules. For

New Medicine Recommendation Opicapone (Ongentys ) 50mg hard capsules. For New Medicine Recommendation Opicapone (Ongentys ) 50mg hard capsules. For adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson's disease

More information

Advanced Therapies for Motor Symptoms in PD. Matthew Boyce MD

Advanced Therapies for Motor Symptoms in PD. Matthew Boyce MD Advanced Therapies for Motor Symptoms in PD Matthew Boyce MD Medtronic Education Teva Speakers Bureau Acadia Speakers Bureau Disclosures Discuss issues in advanced PD Adjunct therapies to levo-dopa Newer

More information

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Parkinsonismm History Parkinson`s disease Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson Definition : Parkinsonism: Parkinsonism is a progressive neurological

More information

Parkinson s Disease. Gillian Sare

Parkinson s Disease. Gillian Sare Parkinson s Disease Gillian Sare Outline Reminder about PD Parkinson s disease in the inpatient Surgical patients with PD Patients who cannot swallow End of life care Parkinson s disease PD is the second

More information

Communicating About OFF Episodes With Your Doctor

Communicating About OFF Episodes With Your Doctor Communicating About OFF Episodes With Your Doctor Early in Parkinson s disease (PD), treatment with levodopa and other anti-pd drugs provides continuous benefit. As the disease progresses, however, symptom

More information

COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date)

COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP Policy agreed by (Vale of York CCG/date) Drug, Treatment, Device name Co-careldopa 2000mg/500mg intestinal gel (Duodopa, Solvay Pharmaceuticals)

More information

Pharmacy Coverage Guidelines are subject to change as new information becomes available.

Pharmacy Coverage Guidelines are subject to change as new information becomes available. ZELAPAR (selegiline hydrochloride) orally disintegrating tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific

More information

Commonly encountered medications and their side effects - what the generalist needs to know

Commonly encountered medications and their side effects - what the generalist needs to know Commonly encountered medications and their side effects - what the generalist needs to know Jeremy Cosgrove Consultant Neurologist Leeds Teaching Hospitals NHS Trust Outline: Parkinson s medications and

More information

Best Medical Treatments for Parkinson s disease

Best Medical Treatments for Parkinson s disease Best Medical Treatments for Parkinson s disease Bernadette Schöneburg, M.D. June 20 th, 2015 What is Parkinson s Disease (PD)? Progressive neurologic disorder that results from the loss of specific cells

More information

New data show sustained 5-year benefit of Neupro (Rotigotine Transdermal System) for symptoms of Restless Legs Syndrome

New data show sustained 5-year benefit of Neupro (Rotigotine Transdermal System) for symptoms of Restless Legs Syndrome New data show sustained 5-year benefit of Neupro (Rotigotine Transdermal System) for symptoms of Restless Legs Syndrome Latest safety and efficacy results for rotigotine in the treatment of moderate to

More information

Rotigotine provided sustained efficacy and tolerability in long term studies of early and late stage idiopathic Parkinson s disease

Rotigotine provided sustained efficacy and tolerability in long term studies of early and late stage idiopathic Parkinson s disease New data presented at the American Academy of Neurology meeting showed that Neupro (rotigotine transdermal system) improved both motor and non-motor symptoms of Parkinson s disease Analysis of RECOVER

More information

GREEN. Ropinirole Other PD treatments Benzodiazepines Opioids low potency Anticonvulsants Clonidine

GREEN. Ropinirole Other PD treatments Benzodiazepines Opioids low potency Anticonvulsants Clonidine New Medicine Report (Adopted by the CCG until review and futher notice) Document Status Traffic Light Decision PRAMIPEXOLE For restless legs syndrome Post Suffolk D&TC GREEN Prescribers Rating Possibly

More information

MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW

MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW MANAGEMENT OF PATIENTS WITH PARKINSON S DISEASE WHO ARE NIL BY MOUTH OR WITH A COMPROMISED SWALLOW Author: Gordon W Duncan Status: Approved Authorised by: Clinical Policy Group Version: 1.0 Review date:

More information

Appendix 2: Admissions checklists for people with Parkinson s

Appendix 2: Admissions checklists for people with Parkinson s Appendix 2: Admissions checklists for people with Parkinson s This document is intended to form the basis of a locally developed tool and so it has been built to be amended with relevant local information,

More information

Evaluation and Management of Parkinson s Disease in the Older Patient

Evaluation and Management of Parkinson s Disease in the Older Patient Evaluation and Management of Parkinson s Disease in the Older Patient David A. Hinkle, MD, PhD Comprehensive Movement Disorders Clinic Pittsburgh Institute for Neurodegenerative Diseases University of

More information

RECOVER analyses highlighted need to address motor, sleep and other non-motor symptoms of Parkinson s disease

RECOVER analyses highlighted need to address motor, sleep and other non-motor symptoms of Parkinson s disease For the attention of Accredited Medical Writers Only RECOVER analyses highlighted need to address motor, sleep and other non-motor symptoms of Parkinson s disease Post hoc analyses of RECOVER study suggested

More information

Rasagiline and Rapid Symptomatic Motor Effect in Parkinson s Disease: Review of Literature

Rasagiline and Rapid Symptomatic Motor Effect in Parkinson s Disease: Review of Literature Neurol Ther (2014) 3:41 66 DOI 10.1007/s40120-013-0014-1 REVIEW Rasagiline and Rapid Symptomatic Motor Effect in Parkinson s Disease: Review of Literature Michele Pistacchi Francesco Martinello Manuela

More information

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS Treatment of Parkinson s Disease and of Spasticity Satpal Singh Pharmacology and Toxicology 3223 JSMBS singhs@buffalo.edu 716-829-2453 1 Disclosures NO SIGNIFICANT FINANCIAL, GENERAL, OR OBLIGATION INTERESTS

More information

Faculty. Joseph Friedman, MD

Faculty. Joseph Friedman, MD Faculty Claire Henchcliffe, MD, DPhil Associate Professor of Neurology Weill Cornell Medical College Associate Attending Neurologist New York-Presbyterian Hospital Director of the Parkinson s Institute

More information

European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations

European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations July 6, 2016 European Commission approves ONGENTYS (opicapone) a novel treatment for Parkinson s disease patients with motor fluctuations Porto, 5 July 2016 BIAL announced that the medicinal product ONGENTYS

More information

Neupro (rotigotine) showed significant benefit on early morning motor control, sleep and nocturnal symptoms in patients with Parkinson s disease

Neupro (rotigotine) showed significant benefit on early morning motor control, sleep and nocturnal symptoms in patients with Parkinson s disease For the attention of accredited medical writers only Neupro (rotigotine) showed significant benefit on early morning motor control, sleep and nocturnal symptoms in patients with Parkinson s disease Detailed

More information

Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs

Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs Introductory Clinical Pharmacology Chapter 32 Antiparkinsonism Drugs Dopaminergic Drugs: Actions Symptoms of parkinsonism are caused by depletion of dopamine in CNS Amantadine: makes more of dopamine available

More information

Treatment of Parkinson s Disease: Present and Future

Treatment of Parkinson s Disease: Present and Future Treatment of Parkinson s Disease: Present and Future Karen Blindauer, MD Professor of Neurology Director of Movement Disorders Program Medical College of Wisconsin Neuropathology: Loss of Dopamine- Producing

More information

Parkinson's Disease and how you can make a difference with medication

Parkinson's Disease and how you can make a difference with medication Parkinson's Disease and how you can make a difference with medication Alyson Franks Parkinson's and Movement Disorder Nurse Specialist Royal Hallamshire Hospital No treatment all Complementary Therapy

More information

DRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer

DRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer DRUG TREATMENT OF PARKINSON S DISEASE Mr. D.Raju, M.pharm, Lecturer PARKINSON S DISEASE (parkinsonism) is a neurodegenerative disorder which affects t h e b a s a l g a n g l i a - and is associated with

More information

What s new for diagnosing and treating Parkinson s Disease?

What s new for diagnosing and treating Parkinson s Disease? What s new for diagnosing and treating Parkinson s Disease? Erika Driver-Dunckley, MD Associate Professor of Neurology Program Director Movement Disorders Fellowship Assistant Program Director Neurology

More information

DRUGS THAT ACT IN THE CNS

DRUGS THAT ACT IN THE CNS DRUGS THAT ACT IN THE CNS Drugs for Neurodegenerative Diseases 2 Dr Karamallah S. Mahmood PhD Clinical Pharmacology 1 DRUGS USED IN PARKINSON S DISEASE/ B. Selegiline and rasagiline Selegiline, also called

More information

Movement Disorders: A Brief Overview

Movement Disorders: A Brief Overview Movement Disorders: A Brief Overview Albert Hung, MD, PhD Massachusetts General Hospital Harvard Medical School August 17, 2006 Cardinal Features of Parkinsonism Tremor Rigidity Bradykinesia Postural imbalance

More information

Early Treatment Options When to start, what with, and why?

Early Treatment Options When to start, what with, and why? September 2014 Early Treatment Options When to start, what with, and why? Dr Doug MacMahon FRCP (Lond. & Edin) dgmacmahon@hotmail.com Disclosure Dr MacMahon has received honoraria, fees for advisory boards,

More information

Parkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust

Parkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust n The Leeds Teaching Hospitals NHS Trust Parkinson s disease Information for patients and carers in partnership with Leeds Community Healthcare NHS Trust The symptoms of Parkinson s appear when the levels

More information

Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn

Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn Objectives What agents do we currently have available and what do we ideally need? What biomarkers exist for

More information

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai Parkinson s disease Therapeutic strategies Surat Tanprawate, MD Division of Neurology University of Chiang Mai 1 Scope Modality of treatment Pathophysiology of PD and dopamine metabolism Drugs Are there

More information

Optimizing Clinical Communication in Parkinson s Disease:

Optimizing Clinical Communication in Parkinson s Disease: Optimizing Clinical Communication in Parkinson s Disease:,Strategies for improving communication between you and your neurologist PFNCA Symposium March 25, 2017 Pritha Ghosh, MD Assistant Professor of

More information

Acute management of in-patient Parkinson s Disease patients

Acute management of in-patient Parkinson s Disease patients Acute management of in-patient Parkinson s Disease patients Contents Pages Introduction and Admission advice 2 Nil by Mouth Guidance 3 5 Complex therapy advice (Apomorphine, DBS, Duodopa) 6 Surgical peri-operative

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis

More information

Cardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms.

Cardinal Features of Parkinson s. Management of Parkinson s Disease. Drug Induced Parkinson s. Other Parkinson s Symptoms. Cardinal Features of Parkinson s Management of Parkinson s Disease Kristin S. Meyer, PharmD, CGP, FASHP Assistant Professor of Pharmacy Practice Drake University & Iowa Veterans Home Spring 2009 Tremor

More information

Patients with Parkinson s disease treated with Neupro (rotigotine) showed low rates of dyskinesias with long term treatment

Patients with Parkinson s disease treated with Neupro (rotigotine) showed low rates of dyskinesias with long term treatment For the attention of accredited medical writers only Patients with Parkinson s disease treated with Neupro (rotigotine) showed low rates of dyskinesias with long term treatment Data presented at the 7

More information

SHARED CARE PRESCRIBING GUIDELINE. TOLCAPONE for the Treatment of IDIOPATHIC PARKISON S DISEASE.

SHARED CARE PRESCRIBING GUIDELINE. TOLCAPONE for the Treatment of IDIOPATHIC PARKISON S DISEASE. WORKING IN PARTNERSHIP WITH Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath) North East Hampshire & Farnham CCG and Crawley, Horsham & Mid-Sussex

More information

Update in the Management of Parkinson s Disease

Update in the Management of Parkinson s Disease Update in the Management of Parkinson s Disease What s standard? What s new? What s coming? Bruno V. Gallo, M.D. Assistant Professor of Neurology, FIU Wertheim College of Medicine Director, Parkinson &

More information

Post hoc analysis from RECOVER study examined effects of Neupro (rotigotine) on surrogate markers of mood and anhedonia in Parkinson s disease

Post hoc analysis from RECOVER study examined effects of Neupro (rotigotine) on surrogate markers of mood and anhedonia in Parkinson s disease For the attention of Accredited Medical Writers Only Post hoc analysis from RECOVER study examined effects of Neupro (rotigotine) on surrogate markers of mood and anhedonia in Parkinson s disease Brussels

More information

Product Information. Sifrol Tablets

Product Information. Sifrol Tablets Sifrol -DL-July 2012-01 1. NAME OF THE MEDICINAL PRODUCT Sifrol 0.25 mg tablets Sifrol 1 mg tablets צהוב=הוספת טקסט. ירוק=מחיקת טקסט. Product Information Sifrol Tablets 2. QUALITATIVE AND QUANTITATIVE

More information

Drug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.)

Drug Management of Parkinsonism. By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.) Drug Management of Parkinsonism By Prof. Mohammad Saleh M. Hassan PhD. (Pharma); MSc. (Ped.); MHPE (Ed.) Drug management of Parkinsonism Levodopa Ergot derivatives noamine Oxidaes Inhibitors Catechol-Omethyl

More information

Data presented at major international congress

Data presented at major international congress Neupro (rotigotine transdermal system) significantly improved wellbeing and daily activities impaired due to limb pain associated with Restless Legs Syndrome Data presented at major international congress

More information

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT MIRAPEXIN 0.088 mg tablets MIRAPEXIN 0.18 mg tablets MIRAPEXIN 0.35 mg tablets MIRAPEXIN 0.7 mg tablets MIRAPEXIN 1.1 mg tablets

More information

Drug treatment of early Parkinson s disease (motor symptoms)

Drug treatment of early Parkinson s disease (motor symptoms) 5 Drug treatment of early Parkinson s disease (motor symptoms) 5.1 When should treatment be started for a patient with Parkinson s disease? 67 5.2 Are there guidelines for the treatment of Parkinson s

More information

Parkinson s Disease Current Treatment Options

Parkinson s Disease Current Treatment Options Parkinson s Disease Current Treatment Options Daniel Kassicieh, D.O., FAAN Sarasota Neurology, P.A. PD: A Chronic Neurodegenerative Ds. 1 Million in USA Epidemiology 50,000 New Cases per Year Majority

More information

2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1).

2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1). Parkinson Disease 1-Parkinson disease (PD) is a chronic, progressive movement disorder resulting from loss of dopamine from the nigrostriatal tracts in the brain, and is characterized by rigidity, bradykinesia,

More information

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following: 1 PARKINSON S DISEASE Parkinson's disease is a long term disease related to the central nervous system that mainly affects the motor system, resulting in the loss of dopamine, which helps in producing

More information

PRODUCT INFORMATION [SIMIPEX XR] (pramipexole hydrochloride monohydrate)

PRODUCT INFORMATION [SIMIPEX XR] (pramipexole hydrochloride monohydrate) PRODUCT INFORMATION [SIMIPEX XR] (pramipexole hydrochloride monohydrate) NAME OF THE MEDICINE Pramipexole hydrochloride monohydrate. The chemical name of pramipexole is (S)-2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole,

More information

Resubmission. Scottish Medicines Consortium

Resubmission. Scottish Medicines Consortium Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals

More information

Report on New Patented Drugs Azilect

Report on New Patented Drugs Azilect Report on New Patented Drugs Azilect Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the Board s Excessive

More information

Parkinson s Disease. Sirilak yimcharoen

Parkinson s Disease. Sirilak yimcharoen Parkinson s Disease Sirilak yimcharoen EPIDEMIOLOGY ~1% of people over 55 years Age range 35 85 years peak age of onset is in the early 60s ~5% of cases characterized by an earlier age of onset (typically

More information

SUMMARY OF PRODUCT CHARACTERISTICS

SUMMARY OF PRODUCT CHARACTERISTICS SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Miramel 0.088 mg, 0.18 mg, and 0.7 mg tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Miramel 0.088 mg tablets: One tablet contains

More information

Margo J Nell Dept Pharmacology

Margo J Nell Dept Pharmacology Margo J Nell Dept Pharmacology 1 The extra pyramidal system Separation of cortico-spinal system (pyramidal system, (PS)) from the basal ganglia (extra pyramidal motor system (EPS)) because they produce

More information

Management of Parkinson s Disease in Primary and Secondary care for patients with compromised swallow or those patients deemed Nil By Mouth.

Management of Parkinson s Disease in Primary and Secondary care for patients with compromised swallow or those patients deemed Nil By Mouth. Management of Parkinson s Disease in Primary and Secondary care for patients with compromised swallow or those patients deemed Nil By Mouth. To aid the management and treatment of Parkinson s Patients

More information

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O. Parkinson s Epidemiology AFFECTS 1% OF POPULATION OVER 65 MEAN AGE OF ONSET 65 MEN:WOMEN 1.5:1 IDIOPATHIC:HEREDITARY 90:10

More information

SHARED CARE PRESCRIBING GUIDELINE

SHARED CARE PRESCRIBING GUIDELINE WORKING IN PARTNERSHIP WITH Surrey (East Surrey CCG, Guildford & Waverley CCG, North West Surrey CCG, Surrey Downs CCG & Surrey Heath) North East Hampshire & Farnham CCG, Crawley CCG, Horsham & Mid-Sussex

More information

Pramipexole hydrochloride. The chemical name of pramipexole is (S)-2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole,

Pramipexole hydrochloride. The chemical name of pramipexole is (S)-2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole, SIFROL and SIFROL ER NAME OF THE MEDICINE Pramipexole hydrochloride. The chemical name of pramipexole is (S)-2-amino-4,5,6,7-tetrahydro-6-propylaminobenzothiazole, [C 10 H 17 N 3 S], CAS registry number

More information

The Shaking Palsy of 1817

The Shaking Palsy of 1817 The Shaking Palsy of 1817 A Treatment Update on Parkinson s Disease Dr Eitzaz Sadiq Neurologist CH Baragwanath Acadamic Hospital Parkinson s Disease O Premature death of dopaminergic neurons O Symptoms

More information

Effective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine

Effective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine Effective Shared Care Agreement (ESCA) for drugs used in dementia- Donepezil, Galantamine, Rivastigmine and Memantine for the treatment of dementia AREAS OF RESPONSIBILITY FOR THE SHARING OF CARE This

More information

05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century

05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century Peter Silburn Professor Clinical Neuroscience University of Queensland Queensland Brain Institute Neurosciences Queensland Impact of in Australia Second most common neurodegenerative disorder Up to 64,000

More information

CLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSON S DISEASE

CLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSON S DISEASE CLINICAL GUIDELINE FOR THE MANAGEMENT OF INPATIENTS WITH PARKINSON S DISEASE 1. Aim/Purpose of this Guideline To assist all doctors and nurses in the care of inpatients with Parkinson s disease. This guideline

More information

Optimizing levodopa therapy for Parkinson s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective

Optimizing levodopa therapy for Parkinson s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective EXPERT OPINION Optimizing levodopa therapy for Parkinson s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective David J Brooks Division of Neuroscience, Faculty

More information

Evidence-Based Medical Review Update: Pharmacological and Surgical Treatments of Parkinson s Disease: 2001 to 2004

Evidence-Based Medical Review Update: Pharmacological and Surgical Treatments of Parkinson s Disease: 2001 to 2004 Movement Disorders Vol. 20, No. 5, 2005, pp. 523 539 2005 Movement Disorder Society Research Review Evidence-Based Medical Review Update: Pharmacological and Surgical Treatments of Parkinson s Disease:

More information